Charles River Laboratories International (NYSE:CRL) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen lowered shares of Charles River Laboratories International (NYSE:CRL) from a buy rating to a hold rating in a report issued on Saturday morning.

A number of other equities research analysts also recently weighed in on CRL. Barclays lowered their target price on shares of Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday. Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. Morgan Stanley set a $185.00 price objective on shares of Charles River Laboratories International in a report on Monday, December 1st. Evercore increased their target price on Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Finally, Bank of America raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target for the company in a research note on Monday, December 15th. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $205.77.

Charles River Laboratories International Trading Up 3.1%

Shares of CRL stock opened at $169.26 on Friday. The company has a market capitalization of $8.33 billion, a PE ratio of -57.18, a price-to-earnings-growth ratio of 5.00 and a beta of 1.63. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $228.88. The business’s fifty day moving average is $200.37 and its 200 day moving average is $179.42. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.10 and a current ratio of 1.29.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The business had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. During the same period in the prior year, the company earned $2.66 EPS. The company’s quarterly revenue was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, equities research analysts anticipate that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CRL. Cardinal Capital Management lifted its stake in shares of Charles River Laboratories International by 0.6% in the 4th quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock valued at $2,180,000 after acquiring an additional 62 shares during the last quarter. Asset Management One Co. Ltd. lifted its position in Charles River Laboratories International by 4.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock valued at $375,000 after purchasing an additional 71 shares during the last quarter. Hantz Financial Services Inc. lifted its position in Charles River Laboratories International by 11.2% in the third quarter. Hantz Financial Services Inc. now owns 793 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 80 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in shares of Charles River Laboratories International by 1.3% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock valued at $1,260,000 after purchasing an additional 80 shares during the period. Finally, Advisory Services Network LLC grew its holdings in shares of Charles River Laboratories International by 2.6% in the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock worth $505,000 after purchasing an additional 83 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.